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Helicobacterpylori is now considered a major pathogen of the upper gastroin-
testinal tract. It is seen as an important cause of peptic ulceration not associat-
ed with NSAID use. It is also increasingly linked to other diseases of the GI
tract, although the relationship between the organism and conditions such as
gastric cancer, non-ulcer dyspepsia and gastroesophageal reflux disease is not
as clear as is the case in peptic ulcer disease. This is probably because ofa lack
of well-performed, statistically powerful, prospective therapeutic trials that
indicate thatH.pylon eradication is ofbenefit in these diseases. The high infec-
tion rate without overt disease seen in many populations, especially from devel-
oping countries, probably contributes to this "credibility gap."
While wehave excellent therapeutic regimens available at this time, rational tar-
geting requires thattheobjective evidence in favoroftherapeutic intervention in
upper GI disease, as well as the local H. pylori epidemiology, needs to be con-
sidered.
INTRODUCTION
Helicobacterpylori was re-introduced to a skeptical gastroenterological community
in 1983. It is of interest to note that even the landmark letters to the Lancet were of dif-
ferent styles: Goodwin records that clinician and histopathologist could not agree on the
wording of a common letter [1]. In his letter, Warren described the histological findings
associated with the unidentified curved bacilli found in active chronic gastritis [2].
Marshall, on the other hand, did not limit himself to describing abnormalities; he extrap-
olated the findings noted, linking them to what was known regarding the association
between gastritis and associated diseases "i.e., peptic ulcer and gastric cancer" [3]. These
original communications appear to have set the scene for the thought processes with
regard toH. pylori in the gastroenterological community. On the one hand, a cautious, evi-
dence-based approach, and on the other, a more intuitive approach, which may be a bit
cavalier for many. This dichotomous approach is also evident when targets for H. pylori
therapy have been defined.
THE NEED FOR TARGETING H. PYLORI THERAPY
There clearly is a need for defining therapeutic targets for H. pylori. Three surveys
have reported on the approach ofgastroenterologists andgeneral practitioners to H. pylori,
dyspepsia and upper gastrointestinal disease. Milne et al. [4] reported that 73 percent of
670 members of the British Society of Gastroenterology thought that H. pylori was a
cause of duodenal ulcer, but that only 25 percent used H. pylori eradication therapy in
duodenal ulcer disease at first presentation. More surprisingly, although 75 percent of
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respondents did not agree that H. pylori was a cause of non-ulcer dyspepsia, 69 percent
used anti-H. pylori therapy to treat patients with this condition.
The situation in general practice appears to be no less confused. Penston and Mistry
[5] report that of the 154 patients treated for H. pylori who they studied, H. pylori status
was known in only one-third of patients before treatment and in only 15 percent after
treatment. In addition, 56 different treatment regimens were used to treat these 154
patients. Not surprisingly, the outcome of treatment was disappointing. Bodger et al. [6]
record a similar confusion in prescribing patterns, with a wide variety ofdiagnoses being
treated for H. pylori.
TARGETING H. PYLORI THERAPY
If a condition that is thought to be related to H. pylori infection is to be specifically
identified as a therapeutic target, the following information pertaining to both H. pylori
and the condition is needed:
1. Can the infection be cured?
2. Is cure ofthe infection permanent or transient?
3. What is the long-term outcome ofthe infection and, related to this, what
is the outcome ofintervention?
Can the infection be cured?
H. pylori therapy has evolved from complicated, high-frequency therapy with a high
side-effect rate ("Triple Therapy"), through a flirtation with proton pump inhibitor (ppI)b
dual therapy (safe, simple, but not universally effective) to the current PPI-based triple
therapy. The latter has come closest to satisfying the criteria for an "ideal" anti-H. pylori
therapy: the regimens are simple, generally well tolerated, with eradication rates general-
ly exceeding 80 percent on an intent-to-treat basis. Further development of these PPI-
based triples is still needed: local resistance profiles have to be elucidated, and the opti-
mal duration ofco-therapy (i.e., seven or ten days, or perhaps even less than seven days)
still has to be determined. Despite these considerations, clinicians currently have effective
therapy available, which, although expensive, is likely to be cost effective in conditions
where the natural history of the disease is effectively changed. The proviso, of course, is
that prescribing habits will change and that physician visits will be reduced following
therapy.
Is cure ofH. pyloripermanent or transient?
Available information suggests that, once effectively treated, cure is permanent in
developed countries, with re-infection rates lower than 1.5 percent [7]. The situation in
developing countries is less well studied. Initial observations suggested re-infection rates
on the order of20 percent per annum in this setting [8], but more recent observations sug-
gest a lower annual re-infection rate, ofthe orderoffive percent per annum [9,10]. Studies
are, however, small and more data are needed before firm conclusions can be drawn
regarding the permanency of cure in the high prevalence setting ofthe developing world.
What is the long-term outcome ofH. pylori infection and therapeutic intervention?
H. pylori infection of the stomach is always associated with gastritis, and H. pylori
has been shown to cause gastritis, fulfilling Koch's postulates [11]. The major conceptual
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problem, however, is that the vast majority of subjects infected with the organism will not
go on to develop any of the specific upper gastrointestinal disease syndromes postulated
to be caused or associated by infection with H. pylori (peptic ulcer disease, gastric carci-
noma, MALT-lymphoma), and the factors determining which subjects will progress from
simple gastritis to a specific disease state are not well defined at present. The relationship
of H. pylori with other major upper gastrointestinal disease syndromes (non-ulcer dys-
pepsia, gastroesophageal reflux disease (GERD) is, at best, speculative.
A major stumbling block to accepting a dominant role forH. pylori in the etiology of
the major upper gastrointestinal disease relates to the inability to reconcile the high infec-
tion rate, especially in developing countries, with the low disease rates reported from these
countries-in short, the "African enigma." Given the inability to prove a causal relation-
ship between H. pylori infection and specific diseases, a lot of emphasis has had to be
placed on the association between infection and disease as well as the effect oftherapeu-
tic intervention, two of the criteria Hill suggested to determine the relationship between
an environmental agent and disease [12].
At this stage, the only disease state in which H. pylori eradication has proven
unequivocally to be beneficial is peptic ulcerdisease, not associated with NSAID use [13].
This benefit appears to be universal [9, 10], sustained [14] and applicable to peptic ulcer-
ation complicated by bleeding [15].
A host of contentious issues remain. Using analytical epidemiological tools, gastric
carcinoma has been linked to H. pylori infection, the organism being classified as a Group
I carcinogen [16]. Non-ulcer dyspepsia is a popular therapeutic target, although the evi-
dence in favor of an etiological role for H. pylori is based on poorly designed, inade-
quately sized studies [17, 18]. More recently, GERD, the one condition ofthe upper gas-
trointestinal tract previously thought to be in no way related to infection with H. pylori,
has become a therapeutic target as a result of a single study suggesting accelerated pro-
gression of fundal gastritis in H. pylori-positive subjects treated with PPIs [19]. This tar-
geting, while conceptually appealing because ofthe historical observations relating to the
migration of H. pylori during PPI therapy, is based on an inherently flawed study, using
as it does two apparently different populations as study subjects and controls.
ATTEMPTS AT THERAPEUTIC TARGETING FOR H. PYLORI
There have been two attempts at targeting therapy for H. pylori. The first, a consen-
sus statement by the National Institutes ofHealth in 1994 [20], followed the conservative,
evidence-based approach in theirrecommendations. Based on available evidence, the NIH
guidelines, as they became known, recommended treatment for H. pylori only in subjects
with documented H. pylori infection and non-NSAID associated peptic ulcer disease.
These guidelines confirmed those of four years earlier, made to the World Congress of
Gastroenterology [21]. The guidelines have two important virtues: they are rugged and
have stood the test of time, while the recommendations can be universally applied.
Specifically, they are as appropriate in the developed world as they are in the developing
world.
It was soon apparent, however, that the "real world" indications for H. pylori thera-
py were being broadened. The European HelicobacterPylori Study Group (EHPSG) has
recently suggested guidelines for the management of H. pylori infection [22]. The
EHPSG combined an evidence-based approach with a consensus-based approach in eval-
uating evidence and making their recommendations. The following resulted: H. pylori
eradication was strongly recommended in all infected peptic ulcerpatients, bleeding pep-
tic ulceration, low-grade MALT lymphoma, gastritis with severe macro- or microscopic
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abnormalities and following resection of early gastric cancer. Eradication was further
considered advisable after appropriate investigation in patients with non-ulcer dyspepsia,
those with a family history of gastric cancer, before long-term PPI therapy in GERD,
when NSAID therapy is planned or ongoing, following gastric surgery for peptic ulcer
disease or gastric cancer and in response to the patient's wishes. The EHPSG were uncer-
tain as to whether eradication should be advised in H. pylori-positive asymptomatic sub-
jects and in those with extra-alimentary disease. The EHPSG suggested, furthermore, that
it is acceptable for dyspeptic patients, younger than 45 years and without "alarm" find-
ings, who test positive for H. pylori, to be treated for the infection without further inves-
tigation at initial presentation.
The EHPSG guidelines represent an important departure from the evidence-based
guidelines ofthe past and can essentially be seen as an attempt to endorse the "real world"
practice. The guidelines have, however, lost their universality. It would be difficult to
apply these guidelines in areas of high gastric cancer prevalence, while the high preva-
lence of the infection (and the low prevalence of disease) in developing countries makes
the testing ofdyspeptic subjects an unproductive waste ofresources.
CONCLUSION
We have come a long way since the isolation ofH. pylori in 1983. Effective therapy
forH. pylori has been developed, and there is still better to come. Peptic ulcer disease has
become medically curable. We are starting to unravel the relationship between the organ-
ism and the causation ofdisease.
The only unequivocally proven target disease for the eradication ofH. pylori remains
H. pylori-associated, non-NSAID driven, peptic ulcer disease. Broader "guidelines"
should be interpreted with care and in the practitioner's local context.
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